AEMPS launches an accelerated evaluation procedure for clinical trials

AEMPS has launched an accelerated evaluation procedure or fast-track with the aim of making Spain a more attractive environment for research into innovative medicines. In general terms, Regulation (EU) No. 536/2014 on clinical trials of medicinal products for human use establishes the maximum deadlines for…

Read MoreAEMPS launches an accelerated evaluation procedure for clinical trials

Learning from Case Law: Non-profit organisations vs the Commission on refusal to grant access to four harmonised standards approved by CEN (Case T‑185/19 and appeal Case C-588/21 P)

Public.Resource.Org, Inc. and Right to Know CLG are both non-profit organisations whose main focus is to make the law freely accessible to all citizens.1 In 2018, they made a request to the European Commission Directorate-General for Internal Market, Industry, Entrepreneurship…

Read MoreLearning from Case Law: Non-profit organisations vs the Commission on refusal to grant access to four harmonised standards approved by CEN (Case T‑185/19 and appeal Case C-588/21 P)

Project Orbis, an FDA initiative to facilitate faster access to innovative cancer therapies

Last updated: 26 March 2025 To see updates, click the’+’ sign below: This post is an attempt to provide some basic information on Project Orbis, an FDA initiative to facilitate faster access to innovative cancer therapies. An important limitation in…

Read MoreProject Orbis, an FDA initiative to facilitate faster access to innovative cancer therapies

European Commission initiative on compulsory licensing of patented inventions and Supplementary Protection Certificates

Last updated: 18 March 2024 See updates at the end of the post. On 27 April 2023, the Commission proposed new rules to help companies, especially small and medium-sized companies (SMEs), make the most of their inventions, leverage new technologies…

Read MoreEuropean Commission initiative on compulsory licensing of patented inventions and Supplementary Protection Certificates

New MHRA guidance on the assessment of established medicines in order to help applicants and shorten time frames

New guidance has been published on the MHRA website concerning process changes for the assessment of established medicines that come into effect on 1 March 2024. This post is an attempt to present the guidance information in a manner that…

Read MoreNew MHRA guidance on the assessment of established medicines in order to help applicants and shorten time frames

European Commission proposes to extend transition periods for certain IVDs, gradual roll-out of Eudamed and an information obligation in case of interruption of supply

Last updated: 23 February 2024 See updated at the end of the post. On 23 January 2024, the European Commission published a proposal to extend transition periods for certain in vitro diagnostic medical devices (IVDs), gradual roll-out of Eudamed and an…

Read MoreEuropean Commission proposes to extend transition periods for certain IVDs, gradual roll-out of Eudamed and an information obligation in case of interruption of supply